Ripretinib Production Cost Reports

The report provides a detailed analysis essential for establishing a ripretinib production plant. It encompasses all critical aspects necessary for ripretinib production, including the cost of ripretinib production, ripretinib plant cost, ripretinib production costs, and the overall ripretinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a ripretinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ripretinib is a type of targeted cancer drug that blocks faulty proteins called KIT and PDGFRα. It is used in adults with advanced gastrointestinal stromal tumour (GIST) who have progressed after treatment with at least three prior kinase inhibitors, including imatinib, sunitinib, and regorafenib. It is administered orally at 150 mg once daily on an empty stomach to stop tumour proliferation by stabilising inactive kinase conformations and blocking downstream signalling pathways. It shows improved progression-free survival and overall response rates in heavily pretreated patients. Its common side effects include hair loss or thinning, tiredness or fatigue, nausea, stomach or abdominal pain, constipation, muscle pain, diarrhoea, decreased appetite, and vomiting.

The market for ripretinib is driven by the rising incidence of gastrointestinal stromal tumours (GIST). Its utilisation in advanced cases resistant to prior kinase inhibitors like imatinib, sunitinib, and regorafenib contributes to its market growth. Other factors such as oncologist adoption, regulatory approvals (FDA and orphan drug status incentives), and Deciphera's oncology focus amid high unmet need in rare cancers fuel its demand. The industrial ripretinib procurement is influenced by premium pricing as a patented speciality drug, limited suppliers reliant on complex synthesis and hospital and pharmacy speciality distribution chains. Also, payer negotiations for rare disease coverage, supply chain vulnerabilities from single-source API production, and competition from emerging therapies impact its sourcing strategies.

Raw Material for Ripretinib Production

According to the ripretinib production plant project report, the key raw materials used in the production of ripretinib include diethyl ester precursor, triethyl orthoformate, acetic anhydride, aqueous ammonia, and phosphorus oxychloride.

Production Process of Ripretinib

The extensive ripretinib production cost report consists of the following major industrial production process:

1. From diethyl ester precursor and triethyl orthoformate: The synthesis of ripretinib starts by making a functionalised 4-aminopyridine intermediate. This is done by reacting diethyl ester with triethyl orthoformate and acetic anhydride, followed by treatment with aqueous ammonia. This pyridine derivative is chlorinated with phosphorus oxychloride, selectively substituted with ethylamine, and then reduced and oxidised to deliver the 4-aminopyridine building block. Separately, an α-aryl ester fragment is prepared from the corresponding acid through a sequence of nitration, esterification and reduction to give the activated aryl ester. The 4-aminopyridine and the α-aryl ester are then coupled via a Knoevenagel and Friedlander-type cyclisation in the presence of potassium fluoride on alumina in DMA to form the central naphthyridone core. After that, methylamine groups are installed on the heterocyclic ring system. Finally, formation of the urea linkage by reaction of the assembled naphthyridine core with phenyl isocyanate gives ripretinib as the final product.

Ripretinib is a kinase inhibitor with the molecular formula C24H21BrFN5O2 and molar mass of 510.37 g/mol. It appears as a white to light yellow solid or off-white powder with high plasma protein binding (≥99% to albumin and α-1-acid glycoprotein). It features a complex structure with bromofluorophenyl, pyrimidine, piperazine, and pyridone rings. It shows good oral bioavailability, a Tmax value of around 4 hours, steady-state in 14 days, and a volume of distribution of 307 L.  It has an elimination half-life of around 15 hours, primarily via faeces after CYP3A4 metabolism to active DP-5439. All these physical and chemical properties  makes it useful as a targeted cancer drug.